The INNOVATION CAMPUS BERLIN is a newly founded dynamic contract research institute with about 400 employees founded by the acquisition of a complete research unit from Bayer.
Decades of experience and top-notch expertise in the field of early pharmaceutical research combined with the spirit of a medium-sized, family owned company create an innovative campus of excellence for early Pharma research.
PRESS PELEASE | BERLIN | NEU-ULM | 18.08.2020
INNOVATION CAMPUS BERLIN is a proud Partner of Europe’s Largest Initiative to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats which is launched today in cooperation with the European Union, the European Federation of Pharmaceutical Industries, Associations (EFPIA) companies and IMI-Associated Partners.
Read the press release:
↓read complete press release | PDF | 899 KB
The INNOVATION CAMPUS BERLIN research center comes with capabilities and capacities spanning the entire drug discovery value chain, including:
We add value to your project at every stage from disease biology to the patient by providing our Innovation Enabling Packages.
We have many years of experiences in the field of drug discovery in the pharmaceutical industry. We translate this expertise into evolving areas such as peptides, PROTACs and RNA-targeting small molecules.
From concept to proof-of-concept - wherever your need is. We join your project collaboratively and professionally. Based on our long-term pharmaceutical research experience we provide you with knowledge on cutting edge drug development, innovative research practice and how to advance your project optimally towards your goal.
On the 1st of July, the "INNOVATION CAMPUS BERLIN" (ICB), a subsidiary of NUVISAN GmbH/ Neu-Ulm officially opened. NUVISAN has taken over a large part of the Berlin-based pharmaceutical research unit, focused on the field of small molecule active ingredients, from Bayer AG and agreed on a strategic partnership.
↓read complete press release | PDF | 472 KB